Bionova Scientific, a CDMO that focuses on protein production, cell line development and process development, announced the grand opening of its commercial-ready, fully single-use good manufacturing practice (GMP) biologics manufacturing center at its headquarters in Fremont, CA. The first clinical supply run at the facility will be completed before the end of this year.
After announcing the project in July 2021 during the pandemic, the CDMO was able to finish construction in under 12 months. At launch, the facility will operate one 1000-liter Cytiva XDR upstream train. A 2000-liter Cytiva system will be added in Q3 of 2022, and depending on demand, a second one will follow.
“It is truly humbling to see this beautiful facility after the tremendous work done by our team over the past year,” says Chung Chun, Bionova co-founder and CTO. “ … We are grateful to the clients who have expressed such trust in our team, and we are energized to start our first clinical production run next month.”